Tesamorelin
Tesamorelin (TH9507)
An FDA-approved GHRH analogue specifically indicated for reducing visceral adiposity in HIV patients with lipodystrophy. Also used off-label for general visceral fat reduction.
Mechanism of Action
Tesamorelin binds to GHRH receptors in the pituitary, stimulating GH release. The resulting GH elevation promotes lipolysis specifically in visceral adipose tissue.
Health Claims & Evidence
Reduces visceral (abdominal) fat
Improves lipid profiles
Cognitive benefits in older adults
Short-Term Effects
Measurable visceral fat reduction within 4–8 weeks.
Long-Term Effects
Sustained visceral fat reduction with continued use. Fat returns upon discontinuation.
Side Effects
Injection site reactions, fluid retention, joint pain, glucose intolerance.
Contraindications
Avoid with active malignancies. Use with caution in diabetics.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Tesamorelin reduces visceral fat in HIV-infected patients
Falutz et al. · New England Journal of Medicine · 2007
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Tesamorelin and related peptides, and prepare an educational research summary.
Explore Research